{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:54:07Z","timestamp":1785772447886,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2025 Open Research Project of the School of Stomatology, Qilu Medical University","award":["KQ25ZF02"],"award-info":[{"award-number":["KQ25ZF02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"DOI":"10.1186\/s12903-026-08737-1","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:59:45Z","timestamp":1781765985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-year follow-up outcomes of neoadjuvant therapy in oral squamous cell carcinoma: an exploratory systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuhan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"10318","key":"8737_CR1","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","volume":"398","author":"MD Mody","year":"2021","unstructured":"Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289\u201399.","journal-title":"Lancet"},{"issue":"8","key":"8737_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","volume":"109","author":"Y Huang","year":"2023","unstructured":"Huang Y, Sun J, Li J, Zhu D, Dong M, Dou S, Tang Y, Shi W, Sun Q, Zhao T, et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). Int J Surg. 2023;109(8):2220\u20137.","journal-title":"Int J Surg"},{"issue":"2\u20133","key":"8737_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cac2.12009","volume":"40","author":"ZH Ren","year":"2020","unstructured":"Ren ZH, Hu CY, He HR, Li YJ, Lyu J. Global and regional burdens of oral cancer from 1990 to 2017: Results from the global burden of disease study. Cancer Commun (Lond). 2020;40(2\u20133):81\u201392.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"8737_CR4","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8737_CR5","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):7348.","journal-title":"Nat Commun"},{"issue":"1","key":"8737_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"8737_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","volume":"13","author":"A Elmusrati","year":"2021","unstructured":"Elmusrati A, Wang J, Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13(1):24.","journal-title":"Int J Oral Sci"},{"issue":"5","key":"8737_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(21)00076-0","volume":"22","author":"C Petit","year":"2021","unstructured":"Petit C, Lacas B, Pignon JP, Le QT, Gr\u00e9goire V, Grau C, Hackshaw A, Zackrisson B, Parmar MKB, Lee JW, et al. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncol. 2021;22(5):727\u201336.","journal-title":"Lancet Oncol"},{"issue":"6","key":"8737_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","volume":"31","author":"LP Zhong","year":"2013","unstructured":"Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr., Sun J, Zhu HG, Tu WY, Li J, Cai YL, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8737_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2003.06.146","volume":"21","author":"L Licitra","year":"2003","unstructured":"Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21(2):327\u201333.","journal-title":"J Clin Oncol"},{"key":"8737_CR11","doi-asserted-by":"crossref","unstructured":"Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer. J Clin Invest 2022, 132(18).","DOI":"10.1172\/JCI161400"},{"key":"8737_CR12","doi-asserted-by":"crossref","unstructured":"Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM. Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023;133(2):e163447.","DOI":"10.1172\/JCI163447"},{"issue":"1","key":"8737_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","volume":"12","author":"Z Mei","year":"2020","unstructured":"Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12(1):16.","journal-title":"Int J Oral Sci"},{"issue":"10212","key":"8737_CR14","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr., Psyrri A, Bast\u00e9 N, Neupane P, Bratland \u00c5, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"4","key":"8737_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr., Psyrri A, Brana I, Bast\u00e9 N, Neupane P, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. J Clin Oncol. 2023;41(4):790\u2013802.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8737_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","volume":"31","author":"RL Ferris","year":"2020","unstructured":"Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942\u201350.","journal-title":"Ann Oncol"},{"issue":"19","key":"8737_CR17","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"key":"8737_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, et al. Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45\u201351.","journal-title":"Oral Oncol"},{"issue":"19","key":"8737_CR19","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II Trial. Clin Cancer Res. 2020;26(19):5140\u201352.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8737_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","volume":"28","author":"TM Wise-Draper","year":"2022","unstructured":"Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28(7):1345\u201352.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8737_CR21","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.","journal-title":"PLoS Med"},{"issue":"5","key":"8737_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4082\/kjfm.23.0034","volume":"44","author":"HJ Seo","year":"2023","unstructured":"Seo HJ, Kim SY, Lee YJ, Park JE. RoBANS 2: A revised risk of bias assessment tool for nonrandomized studies of interventions. Korean J Fam Med. 2023;44(5):249\u201360.","journal-title":"Korean J Fam Med"},{"issue":"6","key":"8737_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3348\/kjr.2015.16.6.1175","volume":"16","author":"KW Kim","year":"2015","unstructured":"Kim KW, Lee J, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part i. general guidance and tips. Korean J Radiol. 2015;16(6):1175\u201387.","journal-title":"Korean J Radiol"},{"issue":"6","key":"8737_CR24","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3348\/kjr.2015.16.6.1188","volume":"16","author":"J Lee","year":"2015","unstructured":"Lee J, Kim KW, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part ii. statistical methods of meta-analysis. Korean J Radiol. 2015;16(6):1188\u201396.","journal-title":"Korean J Radiol"},{"issue":"4","key":"8737_CR25","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1002\/mco2.312","volume":"4","author":"H Ju","year":"2023","unstructured":"Ju H, Wei D, Wu Y, Liu Y, Ding Q, Rui M, Fan Z, Yao Y, Hu J, Ren G. A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent\/metastatic oral squamous cell carcinoma. MedComm (2020). 2023;4(4):e312.","journal-title":"MedComm (2020)"},{"key":"8737_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3332\/ecancer.2021.1325","volume":"15","author":"L Kashyap","year":"2021","unstructured":"Kashyap L, Patil V, Noronha V, Joshi A, Menon N, Jobanputra K, Saha S, Chaturvedi P, Banavali SD, Prabhash K. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). Ecancermedicalscience. 2021;15:1325.","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"8737_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.62347\/EYNT8387","volume":"14","author":"S Kina","year":"2024","unstructured":"Kina S, Miyamoto S, Kawabata-Iwakawa R, Kina-Tanada M, Ogawa M, Yokoo S. Higher overall survival rates of oral squamous cell carcinoma treated with metronomic neoadjuvant chemotherapy. Am J Cancer Res. 2024;14(3):1033\u201351.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"8737_CR28","doi-asserted-by":"publisher","first-page":"103303","DOI":"10.1016\/j.amjoto.2021.103303","volume":"43","author":"GB Stanford-Moore","year":"2022","unstructured":"Stanford-Moore GB, Sola AM, Chan J, El-Sayed I, George J, Ha P, Ryan WR, Heaton CM. Adjuvant therapy improves survival in pT4aN0 oral cavity squamous cell carcinoma with bone invasion. Am J Otolaryngol. 2022;43(2):103303.","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"8737_CR29","doi-asserted-by":"publisher","first-page":"e0231656","DOI":"10.1371\/journal.pone.0231656","volume":"15","author":"R Yoshida","year":"2020","unstructured":"Yoshida R, Nagata M, Hirosue A, Kawahara K, Nakamoto M, Hirayama M, Takahashi N, Matsuoka Y, Sakata J, Nakashima H, et al. Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: a comparative study using the propensity score matching method. PLoS ONE. 2020;15(4):e0231656.","journal-title":"PLoS ONE"},{"issue":"2","key":"8737_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/odi.14471","volume":"30","author":"N Yamakawa","year":"2024","unstructured":"Yamakawa N, Umeda M, Yoshii Y, Mitsudo K, Noguchi M, Kusukawa J, Katakura A, Nakayama H, Sasaki M, Noguchi T, et al. Multicenter retrospective study of nivolumab for recurrent\/metastatic oral squamous cell carcinoma. Oral Dis. 2024;30(2):247\u201358.","journal-title":"Oral Dis"},{"issue":"11","key":"8737_CR31","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.21873\/anticanres.15395","volume":"41","author":"T Naruse","year":"2021","unstructured":"Naruse T, Yanamoto S, Otsuru M, Yamakawa N, Kirita T, Shintani Y, Matsumura T, Okura M, Sasaki M, Ota Y, et al. Multicenter retrospective study of weekly cetuximab plus paclitaxel for recurrent or metastatic oral squamous cell carcinoma. Anticancer Res. 2021;41(11):5785\u201391.","journal-title":"Anticancer Res"},{"issue":"1","key":"8737_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/JS9.0000000000001891","volume":"111","author":"B Li","year":"2025","unstructured":"Li B, Xie S, Han J, Cao H, Lin Z, Hu H, Pan C, Li Q, Li J, Wang L, et al. Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study. Int J Surg. 2025;111(1):781\u201390.","journal-title":"Int J Surg"},{"issue":"6","key":"8737_CR33","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10637-022-01293-9","volume":"40","author":"P Shen","year":"2022","unstructured":"Shen P, Qiao B, Jin N, Wang S. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study. Invest New Drugs. 2022;40(6):1282\u20139.","journal-title":"Invest New Drugs"},{"issue":"2","key":"8737_CR34","doi-asserted-by":"publisher","first-page":"101930","DOI":"10.1016\/j.xcrm.2025.101930","volume":"6","author":"HM Liu","year":"2025","unstructured":"Liu HM, Xiong XP, Yu ZL, Shao Z, Chen GL, Liu YT, Wang XX, Fu QY, Cheng XX, Li J, et al. Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. Cell Rep Med. 2025;6(2):101930.","journal-title":"Cell Rep Med"},{"issue":"1","key":"8737_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","volume":"15","author":"Y Tan","year":"2023","unstructured":"Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J, Huang C. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023;15(1):44.","journal-title":"Int J Oral Sci"},{"issue":"3","key":"8737_CR36","doi-asserted-by":"publisher","first-page":"104235","DOI":"10.1016\/j.amjoto.2024.104235","volume":"45","author":"GP Sexton","year":"2024","unstructured":"Sexton GP, Hintze JM, Walsh P, Moriarty F, Lennon P, Fitzgerald CWR, O\u2019Neill JP. Epidemiology and management of oral cavity squamous cell carcinoma in Ireland. Am J Otolaryngol. 2024;45(3):104235.","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"8737_CR37","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.4317\/medoral.26047","volume":"29","author":"I Amezaga-Fernandez","year":"2024","unstructured":"Amezaga-Fernandez I, Aguirre-Urizar JM, Su\u00e1rez-Pe\u00f1aranda JM, Chamorro-Petronacci C, Lafuente-Ib\u00e1\u00f1ez de Mendoza I, Marichalar-Mendia X, Blanco-Carri\u00f3n A, Ant\u00fanez-L\u00f3pez J, Garc\u00eda-Garc\u00eda A. Epidemiological, clinical, and prognostic analysis of oral squamous cell carcinoma diagnosed and treated in a single hospital in Galicia (Spain): a retrospective study with 5-year follow-up. Med Oral Patol Oral Cir Bucal. 2024;29(1):e36\u201343.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"8737_CR38","doi-asserted-by":"publisher","first-page":"105207","DOI":"10.1016\/j.critrevonc.2026.105207","volume":"221","author":"F Carosi","year":"2026","unstructured":"Carosi F, Filippini DM, Fabbri L, Carlini A, Monte A, Sgarzi M, Fermi M, Querzoli G, Romaniello D, Mercante G, et al. Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers. Crit Rev Oncol Hematol. 2026;221:105207.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"8737_CR39","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1007\/s00405-025-09707-z","volume":"282","author":"DM Filippini","year":"2025","unstructured":"Filippini DM, Carosi F, Querzoli G, Sabbioni S, Fermi M, Chiari F, Gili R, Pantaleo MA, Succo G, Molteni G, et al. Challenges in pathological diagnosis of rare head and neck cancers: National survey and retrospective study. Eur Arch Otorhinolaryngol. 2025;282(12):6465\u201375.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"8737_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00428-024-03837-1","volume":"485","author":"RA Ghossein","year":"2024","unstructured":"Ghossein RA, Dogan S, Cohen MA, Katabi N, Xu B. Histologic spectrum and outcome of Human papillomavirus (HPV)-associated oral cavity squamous cell carcinoma: a single center experience and a survey of The Cancer Genome Atlas (TGCA) cohort. Virchows Arch. 2024;485(4):665\u201374.","journal-title":"Virchows Arch"},{"issue":"2","key":"8737_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jamaoto.2025.4573","volume":"152","author":"EV Mastrolonardo","year":"2026","unstructured":"Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, et al. Pathologic response and survival after neoadjuvant immunotherapy for resectable mucosal HNSCC: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2026;152(2):191\u20138.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"8737_CR42","doi-asserted-by":"crossref","unstructured":"Okuyama K, Naruse T, Matsushita Y, Fujimoto J, Yanamoto S, Lei YL, Hu J. Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges. Mol Cancer. 2026;25(1):120.","DOI":"10.1186\/s12943-026-02609-6"},{"issue":"4","key":"8737_CR43","doi-asserted-by":"publisher","first-page":"101902","DOI":"10.1016\/j.gendis.2025.101902","volume":"13","author":"Y Zhi","year":"2026","unstructured":"Zhi Y, Ren W, Li S, Zheng J, Song J, Gao L, Zhi K. Immune patterns of the tumor microenvironment in PD-L1(+) EGFR(+) HNSCC patients received anti-PD-1 and EGFR-based neoadjuvant therapy. Genes Dis. 2026;13(4):101902.","journal-title":"Genes Dis"},{"key":"8737_CR44","doi-asserted-by":"crossref","unstructured":"Chiari F, Filippini DM, Fermi M, Presutti L, Caporale CD, Bertino G, Benazzo M, Locati LD, Guarino P. Survival behavior of patients treated with curative and palliative electrochemotherapy for oral and oropharyngeal cancer: a systematic review. Eur Arch Otorhinolaryngol 2025.","DOI":"10.1007\/s00405-025-09843-6"},{"issue":"3","key":"8737_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.21.00179","volume":"40","author":"D Chaukar","year":"2022","unstructured":"Chaukar D, Prabash K, Rane P, Patil VM, Thiagarajan S, Ghosh-Laskar S, Sharma S, Pai PS, Chaturvedi P, Pantvaidya G, et al. Prospective phase ii open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. J Clin Oncol. 2022;40(3):272\u201381.","journal-title":"J Clin Oncol"},{"issue":"17","key":"8737_CR46","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.ejca.2015.08.007","volume":"51","author":"GN Marta","year":"2015","unstructured":"Marta GN, Riera R, Bossi P, Zhong LP, Licitra L, Macedo CR, de Castro Junior G, Carvalho AL, William WN Jr., Kowalski LP. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. Eur J Cancer. 2015;51(17):2596\u2013603.","journal-title":"Eur J Cancer"},{"issue":"4","key":"8737_CR47","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000357712","volume":"86","author":"N Denaro","year":"2014","unstructured":"Denaro N, Russi EG, Adamo V, Merlano MC. State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. Oncology. 2014;86(4):212\u201329.","journal-title":"Oncology"},{"key":"8737_CR48","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.lansea.2026.100743","volume":"47","author":"PK Marimuthu","year":"2026","unstructured":"Marimuthu PK, Renukaradhya C, Sahu S, John AO, Tirkey AJ, Sasidharan BK, Vidya K, Riju J, Agrawal M, Thomas M, et al. Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial. Lancet Reg Health Southeast Asia. 2026;47:100743.","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"21","key":"8737_CR49","doi-asserted-by":"publisher","first-page":"18707","DOI":"10.18632\/oncotarget.4531","volume":"6","author":"LP Zhong","year":"2015","unstructured":"Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr., Hong CS, Sun J, Zhu HG, Tu WY, Li J, et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 2015;6(21):18707\u201314.","journal-title":"Oncotarget"},{"issue":"3","key":"8737_CR50","first-page":"207","volume":"17","author":"R Tabrizi","year":"2016","unstructured":"Tabrizi R, Garajei A, Shafie E, Jamshidi S. Outcome of neoadjuvant chemotherapy on local recurrence and distant metastasis of oral squamous cell carcinoma: a retrospective study. J Dent (Shiraz). 2016;17(3):207\u201312.","journal-title":"J Dent (Shiraz)"},{"key":"8737_CR51","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.2147\/CMAR.S204961","volume":"11","author":"X Su","year":"2019","unstructured":"Su X, Liu Q, Li J, Zhang C, Xue Z, He C, Liu W. The oncological outcome and influence of neoadjuvant chemotherapy on the surgery in the resectable and locally advanced oral squamous cell carcinoma. Cancer Manag Res. 2019;11:7039\u201346.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"8737_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hed.10373","volume":"26","author":"C Klug","year":"2004","unstructured":"Klug C, Keszthelyi D, Ploder O, Sulzbacher I, Voracek M, Wagner A, Millesi W, Kornek G, Kainberger F, Kermer C, et al. Neoadjuvant radiochemotherapy of oral cavity and oropharyngeal cancer: evaluation of tumor response by CT differs from histopathologic response assessment in a significant fraction of patients. Head Neck. 2004;26(3):224\u201331.","journal-title":"Head Neck"},{"key":"8737_CR53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1477-7819-11-67","volume":"11","author":"J Ma","year":"2013","unstructured":"Ma J, Liu Y, Yang X, Zhang CP, Zhang ZY, Zhong LP. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. World J Surg Oncol. 2013;11:67.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"8737_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/ijc.IJC_131_17","volume":"54","author":"AH Rudresha","year":"2017","unstructured":"Rudresha AH, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Jacob LA, Suresh Babu MC, Lokesh KN, Rajeev LK. Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: A regional cancer center experience. Indian J Cancer. 2017;54(1):35\u20138.","journal-title":"Indian J Cancer"},{"issue":"10","key":"8737_CR55","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.oraloncology.2014.07.015","volume":"50","author":"VM Patil","year":"2014","unstructured":"Patil VM, Prabhash K, Noronha V, Joshi A, Muddu V, Dhumal S, Arya S, Juvekar S, Chaturvedi P, Chaukar D, et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers. Oral Oncol. 2014;50(10):1000\u20134.","journal-title":"Oral Oncol"},{"issue":"10","key":"8737_CR56","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.xcrm.2021.100426","volume":"2","author":"HM Knochelmann","year":"2021","unstructured":"Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, et al. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021;2(10):100426.","journal-title":"Cell Rep Med"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-026-08737-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08737-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-026-08737-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:03:21Z","timestamp":1785769401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12903-026-08737-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8737"],"URL":"https:\/\/doi.org\/10.1186\/s12903-026-08737-1","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a meta-analysis based solely on published literature retrieved from public databases (PubMed, Embase, and the Cochrane Library). Since no identifiable individual patient data were involved, ethical approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1369"}}